1.4. 参考文献
[1] G. Koren, “Special Aspects of Perinatal & Pediatric Pharmacology,” Basicmedical Key. [Online]. Available: https://basicmedicalkey.com/special-aspects-of-perinatal- pediatric-pharmacology/.
[2] A. L. Christianson, C. P. Howson, and B. Modell, Global report on birth defects: the hidden toll of dying and disabled children. March of Dimes Birth Defects Foundation, 2006.
[3] E. Gilbert-Barness, “Teratogenic causes of malformations,” Ann. Clin. Lab. Sci., vol. 40, no. 2, pp. 99–114, Spring 2010.
[4] J. Bailey, A. Knight, and J. Balcombe, “The Future of Teratology Research is In Vitro,” 2005.
[5] R. W. Smithells and C. G. Newman, “Recognition of thalidomide defects,” J. Med. Genet., vol. 29, no. 10, pp. 716–723, Oct. 1992.
[6]日本毒性学会教育委員会, Ed.,トキシコロジー （第 3 版）5 章毒性試験法.朝倉書店, 2018年03月05日.
[7] J. M. DeSesso, “Future of developmental toxicity testing,” Current Opinion in Toxicology, vol. 3, pp. 1–5, Apr. 2017.
[8] The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), “ICH S5 (R3) guideline on reproductive toxicology: Detection of toxicity to reproduction for human pharmaceuticals - step 5.” Feb-2020.
[9]小島肇, “代替法試験の基礎から最新知見まで,” 2016年7月8日.
[10]小島肇, “ボロニア宣言.” [Online]. Available: http://www.asas.or.jp/jsaae/alternative/index.html. [Accessed: 2020年9月12日].
[11] C. Zhang, J. Ball, J. Panzica-Kelly, and K. Augustine-Rauch, “In Vitro Developmental Toxicology Screens: A Report on the Progress of the Methodology and Future Applications,” Chem. Res. Toxicol., vol. 29, no. 4, pp. 534–544, Apr. 2016.
[12] E. Genschow et al., “The ECVAM International Validation Study on In Vitro Embryotoxicity Tests: Results of the Definitive Phase and Evaluation of Prediction Models,” Altern. Lab. Anim., vol. 30, no. 2, pp. 151–176, Mar. 2002.
[13] E.-J. Hong and E.-B. Jeung, “Assessment of Developmental Toxicants using Human Embryonic Stem Cells,” Toxicol. Res. , vol. 29, no. 4, pp. 221–227, Dec. 2013.
[14] C. Estevan, A. C. Romero, D. Pamies, E. Vilanova, and M. A. Sogorb, “Embryonic stem cells in toxicological studies,” Embryonic Stem Cells. PM Kallos, InTech, pp. 213–230, 2011.
[15] European Chemicals Agency (ECHA), “Committee for Risk Assessment (RAC) Opinion proposing harmonised classification and labelling at EU levels of Methylmercuric chloride.” 15-Mar-2017.
[16] N. Suzuki, S. Ando, N. Yamashita, N. Horie, and K. Saito, “Evaluation of novel high-throughput embryonic stem cell tests with new molecular markers for screening embryotoxic chemicals in vitro,” Toxicol. Sci., vol. 124, no. 2, pp. 460–471, Dec. 2011.
[17] F. Uibel, C. Koehle, and M. Schwarz, “In vitro prediction of teratogenic effects using pathway-specific reporters: the ReProGlo assay,” in NAUNYN- SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2009, vol. 379, pp. 88–88.
[18] J. J. Sanz-Ezquerro, A. E. Münsterberg, and S. Stricker, “Editorial: Signaling Pathways in Embryonic Development,” Frontiers in Cell and Developmental Biology, vol. 5. 2017.
[19] A. F. Elsaid, E. C. Délot, and M. D. Collins, “Differential perturbation of the Fgf/Erk1/2 and Shh pathways in the C57BL/6N and SWV embryonic limb buds after mid-gestational cadmium chloride administration,” Mol. Genet. Metab., vol. 92, no. 3, pp. 258–270, Nov. 2007.
[20] T. Asatsuma-Okumura, T. Ito, and H. Handa, “Molecular mechanisms of cereblon- based drugs,” Pharmacol. Ther., vol. 202, pp. 132–139, Oct. 2019.
[21] F. Uibel et al., “ReProGlo: a new stem cell-based reporter assay aimed to predict embryotoxic potential of drugs and chemicals,” Reprod. Toxicol., vol. 30, no. 1, pp. 103–112, Aug. 2010.
[22] F. Uibel and M. Schwarz, “ReProGlo: A NEW STEM-CELL-BASED HIGH- THROUGHPUT ASSAY TO PREDICT THE EMBRYOTOXIC POTENTIAL OF CHEMICALS,” High-Throughput Screening Methods in Toxicity Testing, p. 343, 2013.
[23] A. Inoue et al., “Comparative study of the zebrafish embryonic toxicity test and mouse embryonic stem cell test to screen developmental toxicity of human pharmaceutical drugs,” Fundamental Toxicological Sciences, vol. 3, no. 2. pp. 79– 87, 2016.
[24] H. Nagahori, N. Suzuki, F. Le Coz, T. Omori, and K. Saito, “Prediction of in vivo developmental toxicity by combination of Hand1-Luc embryonic stem cell test and metabolic stability test with clarification of metabolically inapplicable candidates,” Toxicol. Lett., vol. 259, pp. 44–51, Sep. 2016.
[25] F. Uibel and M. Schwarz, “Prediction of embryotoxic potential using the ReProGlo stem cell-based Wnt reporter assay,” Reprod. Toxicol., vol. 55, pp. 30–49, Aug. 2015.
[26] J. Baumann et al., “Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events,” Archives of Toxicology, vol. 90, no. 6. pp. 1415–1427, 2016.
[27] “iPS 細胞とは？,”京都大学iPS 研究所CiRA. [Online]. Available: https://www.cira.kyoto-u.ac.jp/j/faq/faq_ips.html.
[28] N. Aikawa, A. Kunisato, K. Nagao, H. Kusaka, K. Takaba, and K. Ohgami, “Detection of thalidomide embryotoxicity by in vitro embryotoxicity testing based on human iPS cells,” J. Pharmacol. Sci., vol. 124, no. 2, pp. 201–207, Jan. 2014.
[29] E. de Jong, L. van Beek, and A. H. Piersma, “Comparison of osteoblast and cardiomyocyte differentiation in the embryonic stem cell test for predicting embryotoxicity in vivo,” Reprod. Toxicol., vol. 48, pp. 62–71, Sep. 2014.
[30] M. A. Lemmon and J. Schlessinger, “Cell signaling by receptor tyrosine kinases,” Cell, vol. 141, no. 7, pp. 1117–1134, Jun. 2010.
2.6. 参考文献
[1] J. J. Sanz-Ezquerro, A. E. Münsterberg, and S. Stricker, “Editorial: Signaling Pathways in Embryonic Development,” Frontiers in Cell and Developmental Biology, vol. 5. 2017.
[2] M. A. Lemmon and J. Schlessinger, “Cell signaling by receptor tyrosine kinases,” Cell, vol. 141, no. 7, pp. 1117–1134, Jun. 2010.
[3] S. M. Morgani et al., “A Sprouty4 reporter to monitor FGF/ERK signaling activity in ESCs and mice,” Dev. Biol., vol. 441, no. 1, pp. 104–126, Sep. 2018.
[4] W. Salem et al., “Imatinib treatments have long-term impact on placentation and embryo survival,” Sci. Rep., vol. 9, no. 1, pp. 1–10, Feb. 2019.
[5] A. F. Elsaid, E. C. Délot, and M. D. Collins, “Differential perturbation of the Fgf/Erk1/2 and Shh pathways in the C57BL/6N and SWV embryonic limb buds after mid-gestational cadmium chloride administration,” Mol. Genet. Metab., vol. 92, no. 3, pp. 258–270, Nov. 2007.
[6] T. Asatsuma-Okumura, H. Ando, and M. De Simone, “p63 is a cereblon substrate involved in thalidomide teratogenicity,” Nat. Chem. Biol., 2019.
[7] F. Gualdrini, C. Esnault, S. Horswell, A. Stewart, N. Matthews, and R. Treisman, “SRF co-factors control the balance between cell proliferation and contractility,” Mol. Cell, vol. 64, no. 6, pp. 1048–1061, Dec. 2016.
[8] H. N. Vasudevan and P. Soriano, “SRF regulates craniofacial development through selective recruitment of MRTF cofactors by PDGF signaling,” Dev. Cell, vol. 31, no. 3, pp. 332–344, Nov. 2014.
[9] C. A. Franco et al., “Serum Response Factor Is Required for Sprouting Angiogenesis and Vascular Integrity,” Dev. Cell, vol. 15, no. 3, pp. 448–461, Sep. 2008.
[10] “レポーター遺伝子アッセイ,” Thermo Fisher Scientific. [Online]. Available: https://www.thermofisher.com/jp/ja/home/life-science/protein-biology/protein- assays-analysis/reporter-gene-assays.html. [Accessed: 2021年9月14日].
[11] “Luciferase Bioluminescence Technology Guide,” Promega. [Online]. Available: https://www.promega.co.jp/jp/jp_tech/jp_manuals/Luciferase.pdf. [Accessed: 2021年9月15日].
[12] M. P. Hall et al., “Engineered luciferase reporter from a deep sea shrimp utilizing a novel imidazopyrazinone substrate,” ACS Chem. Biol., vol. 7, no. 11, pp. 1848–1857, Nov. 2012.
[13] “NanoLuc® Luciferase Technology,” Promega. [Online]. Available: https://www.promega.co.jp/products/tech/nanoluc_tech/. [Accessed: 2021年9月15日].
[14] “ 発光レポーターガイ ド,” Promega. [Online]. Available: https://www.promega.co.jp/pdf/tech/reporter_guide.pdf. [Accessed: 2021年9月15日].
[15]斎藤哲一郎室山優子, “転写制御因子,” 脳科学辞典, 2014年1月20日. [Online]. Available: https://bsd.neuroinf.jp/wiki/%E8%BB%A2%E5%86%99%E5%88%B6%E5%BE%A1 %E5%9B%A0%E5%AD%90. [Accessed: 2021年9月15日].
[16] 田渕明子, “血清応答因子,” 脳科学辞典, 2012年5月12日. [Online]. Available: https://bsd.neuroinf.jp/wiki/%E8%A1%80%E6%B8%85%E5%BF%9C%E7%AD%94 %E5%9B%A0%E5%AD%90. [Accessed: 2021年9月15日].
[17] B. D. Almond, “A Rapid-Fire Solution,” Promega. [Online]. Available: https://www.promega.co.jp/jp/prometec_J/pdf/pj14/PJ-No14-03.pdf. [Accessed: 2021年9月15日].
[18] 上平正道, “動物細胞への遺伝子導入,” 生物工学会誌, vol. 95, no. 12, pp. 734–738, 2017.
[19]林悠, “トランスジェニック動物,” 脳科学辞典, 2013年3月18日. [Online]. Available: https://bsd.neuroinf.jp/wiki/%E3%83%88%E3%83%A9%E3%83%B3%E3%82%B9% E3%82%B8%E3%82%A7%E3%83%8B%E3%83%83%E3%82%AF%E5%8B%95%E7 %89%A9. [Accessed: 2021年9月16日].
[20] R. C. DeKelver et al., “Functional genomics, proteomics, and regulatory DNA analysis in isogenic settings using zinc finger nuclease-driven transgenesis into a safe harbor locus in the human genome,” Genome Res., vol. 20, no. 8, pp. 1133–1142, Aug. 2010.
[21] “サンガーシーケンス解析,”株式会社日本遺伝子研究所. [Online]. Available: http://ngrl.co.jp/category4/qpcr/service2. [Accessed: 2021年9月20日].
[22] “次世代シーケンシング(NGS)とは,”コスモ・バイオ株式会社. [Online]. Available: https://www.cosmobio.co.jp/support/technology/a/next-generation-sequencing- introduction-apb.asp. [Accessed: 2021年9月20日].
3.7. 参考文献
[1] J. Zischewski, R. Fischer, and L. Bortesi, “Detection of on-target and off-target mutations generated by CRISPR/Cas9 and other sequence-specific nucleases,” Biotechnol. Adv., vol. 35, no. 1, pp. 95–104, Jan. 2017.
[2]山本卓, “ゲノム編集の歴史と基礎.” .
[3]山本卓,坂本尚昭, and佐久間哲史, “部位特異的ヌクレアーゼを基盤とするゲノム編集技術,”ウイルス, vol. 64, no. 1, pp. 75–82, 2014.
[4] 上平正道, “動物細胞への遺伝子導入,” 生物工学会誌, vol. 95, no. 12, pp. 734–738, 2017.
[5]今村公紀 , 中島龍介, “iPS 細 胞 ,” 脳 科学辞典. [Online]. Available: https://bsd.neuroinf.jp/wiki/IPS%E7%B4%B0%E8%83%9E. [Accessed: 2021年12月1日].
[6] S. Liedtke et al., “DNA damage response in neonatal and adult stromal cells compared with induced pluripotent stem cells,” Stem Cells Transl. Med., vol. 4, no. 6, pp. 576–589, Jun. 2015.
[7] G. Laschinski, R. Vogel, and H. Spielmann, “Cytotoxicity test using blastocyst- derived euploid embryonal stem cells: a new approach to in vitro teratogenesis screening,” Reprod. Toxicol., vol. 5, no. 1, pp. 57–64, 1991.
[8] N. Aikawa, “A novel screening test to predict the developmental toxicity of drugs using human induced pluripotent stem cells,” J. Toxicol. Sci., vol. 45, no. 4, pp. 187– 199, 2020.
[9] M. Scanu, L. Mancuso, and G. Cao, “Evaluation of the use of human Mesenchymal Stem Cells for acute toxicity tests,” Toxicol. In Vitro, vol. 25, no. 8, pp. 1989–1995, Dec. 2011.
[10] M. A. Lemmon and J. Schlessinger, “Cell signaling by receptor tyrosine kinases,” Cell, vol. 141, no. 7, pp. 1117–1134, Jun. 2010.
[11] N. Su, M. Jin, and L. Chen, “Role of FGF/FGFR signaling in skeletal development and homeostasis: learning from mouse models,” Bone Res, vol. 2, p. 14003, Apr. 2014.
[12] M. D. Tallquist and P. Soriano, “Cell autonomous requirement for PDGFRalpha in populations of cranial and cardiac neural crest cells,” Development, vol. 130, no. 3, pp. 507–518, Feb. 2003.
[13] C. Wang et al., “Type 1 Fibroblast Growth Factor Receptor in Cranial Neural Crest Cell-derived Mesenchyme Is Required for Palatogenesis *,” J. Biol. Chem., vol. 288, no. 30, pp. 22174–22183, Jul. 2013.
[14] J. M. Verheyden, M. Lewandoski, C. Deng, B. D. Harfe, and X. Sun, “Conditional inactivation of Fgfr1 in mouse defines its role in limb bud establishment, outgrowth and digit patterning,” Development, vol. 132, no. 19, pp. 4235–4245, Oct. 2005.
[15] S. Moosa and B. Wollnik, “Altered FGF signalling in congenital craniofacial and skeletal disorders,” Semin. Cell Dev. Biol., vol. 53, pp. 115–125, May 2016.
[16] F. Gualdrini, C. Esnault, S. Horswell, A. Stewart, N. Matthews, and R. Treisman, “SRF co-factors control the balance between cell proliferation and contractility,” Mol. Cell, vol. 64, no. 6, pp. 1048–1061, Dec. 2016.
[17] H. N. Vasudevan and P. Soriano, “SRF regulates craniofacial development through selective recruitment of MRTF cofactors by PDGF signaling,” Dev. Cell, vol. 31, no. 3, pp. 332–344, Nov. 2014.
4.8. 参考文献
[1] E. Genschow et al., “The ECVAM International Validation Study on In Vitro Embryotoxicity Tests: Results of the Definitive Phase and Evaluation of Prediction Models,” Altern. Lab. Anim., vol. 30, no. 2, pp. 151–176, Mar. 2002.
[2] D. M. Ornitz and N. Itoh, “The Fibroblast Growth Factor signaling pathway,” Wiley Interdisciplinary Reviews: Developmental Biology, vol. 4, no. 3. pp. 215–266, 2015.
[3] J. L. Campbell Jr, M. A. Smith, and J. W. Fisher, “Dose‐response for retinoic acid‐ induced forelimb malformations and cleft palate: a comparison of computerized image analysis and visual inspection,” Research Part B …, 2004.
[4] T. Okuda, H. Takakuwa, M. Mikami, H. Miyamoto, and N. Manabe, “Retinoic Acid Induces Malformations Related to Cell Death in the Developing Mouse Embryo,” J. Reprod. Dev., vol. 43, no. 1, pp. 59–64, 1997.
[5] A. E. Schlisser and B. F. Hales, “Deprenyl enhances the teratogenicity of hydroxyurea in organogenesis stage mouse embryos,” Toxicol. Sci., vol. 134, no. 2, pp. 391–399, Aug. 2013.
[6] S. C. Hyoun, S. G. Običan, and A. R. Scialli, “Teratogen update: methotrexate,” Birth Defects Res. A Clin. Mol. Teratol., vol. 94, no. 4, pp. 187–207, Apr. 2012.
[7] A. Haryono, T. W. Surjono, L. A. Sutasurya, and S. Sudarwati, “Methoxyacetic Acid Induced Apoptosis on the Forelimb Bud of Swiss Webster Mice,” HAYATI Journal of Biosciences, vol. 18, no. 1, pp. 33–36, Mar. 2011.
[8] “GHS Classification Results,” National Institute of Technology and Evaluation (NITE). [Online]. Available: https://www.nite.go.jp/chem/english/ghs/all_fy_e.html. [Accessed: 2021年10月03日].
[9] M.-Q. Su and G. T. Okita, “Embryocidal and teratogenic effects of methylmercury in mice,” Toxicology and Applied Pharmacology, vol. 38, no. 1. pp. 207–216, 1976.
[10] S. Tanaka et al., “STUDIES ON TERATOGENIC EFFECT OF SALICYLIC ACID AND ASPIRIN IN RATS AS RELATED TO FETAL DISTRIBUTION,” official journal of Congeital Anomalies Research Association of Japan, vol. 13, no. 2, pp. 73– 84, 1973.
[11] M. A. Joschko, I. E. Dreosti, and R. S. Tulsi, “The teratogenic effects of salicylic acid on the developing nervous system in rats in vitro,” Teratology, vol. 48, no. 2, pp. 105– 114, Aug. 1993.
[12]E. Rodríguez-Pinilla, I. Arroyo, J. Fondevilla, M. J. García, and M. L. Martínez-Frías, “Prenatal exposure to valproic acid during pregnancy and limb deficiencies: A case- control study,” Am. J. Med. Genet., vol. 90, no. 5, pp. 376–381, 2000.
[13] F.-H. Paradis and B. F. Hales, “Exposure to valproic acid inhibits chondrogenesis and osteogenesis in mid-organogenesis mouse limbs,” Toxicol. Sci., vol. 131, no. 1, pp. 234–241, Jan. 2013.
[14] E. Genschow et al., “Validation of the Embryonic Stem Cell Test in the International ECVAM Validation Study on Three In Vitro Embryotoxicity Tests,” Alternatives to Laboratory Animals, vol. 32, no. 3. pp. 209–244, 2004.
[15] “ 細胞増殖/ 細胞毒性アッセイキット,”同仁化学研究所. [Online]. Available: https://www.dojindo.co.jp/products/CK04/. [Accessed: 2021年10月05日].
[16] C. Ritz, F. Baty, J. C. Streibig, and D. Gerhard, “Dose-Response Analysis Using R,” PLoS One, vol. 10, no. 12, p. e0146021, Dec. 2015.
[17] A. Perperoglou, W. Sauerbrei, M. Abrahamowicz, and M. Schmid, “A review of spline function procedures in R,” BMC Med. Res. Methodol., vol. 19, no. 1, p. 46, Mar. 2019.
[18] Madoka, “Runge’s phenomenon.pdf.” 2006.
[19] S. Wood, “Mixed GAM computation vehicle with GCV/AIC/REML smoothness estimation and GAMMs by REML/PQL,” R package version, pp. 1–8, 2018.
[20] Social Survey Research Information Co. , Ltd., “ROC曲線,” 統計 WEB. [Online]. Available: https://bellcurve.jp/statistics/glossary/2167.html. [Accessed: 2021年10月08日].
[21] G. M. Sullivan and R. Feinn, “Using Effect Size-or Why the P Value Is Not Enough,” J. Grad. Med. Educ., vol. 4, no. 3, pp. 279–282, Sep. 2012.
[22] C. R. Brydges, “Effect Size Guidelines, Sample Size Calculations, and Statistical Power in Gerontology,” Innovation in Aging, vol. 3, no. 4. 2019.
[23] J. A. Swets, “Measuring the accuracy of diagnostic systems,” Science, vol. 240, no. 4857, pp. 1285–1293, Jun. 1988.
[24] A. L. Luz and E. J. Tokar, “Pluripotent Stem Cells in Developmental Toxicity Testing: A Review of Methodological Advances,” Toxicol. Sci., vol. 165, no. 1, pp. 31–39, Sep. 2018.
[25] S. H. Gilani, “Congenital abnormalities in methylmercury poisoning,” Environ. Res., vol. 9, no. 2, pp. 128–134, Apr. 1975.
[26] European Chemicals Agency (ECHA), “Committee for Risk Assessment (RAC) Opinion proposing harmonised classification and labelling at EU levels of Methylmercuric chloride.” 15-Mar-2017.
[27] K. Kobayashi et al., “Editor’s Highlight: Development of Novel Neural Embryonic Stem CellTests for High-Throughput Screening of Embryotoxic Chemicals,” Toxicol. Sci., vol. 159, no. 1, pp. 238–250, Sep. 2017.
[28] N. Nakamura, M. Fujioka, and C. Mori, “Alteration of programmed cell death and gene expression by 5-bromodeoxyuridine during limb development in mice,” Toxicol. Appl. Pharmacol., 2000.
[29] A. Honda, M. Iwama, T. Umeda, and Y. Mori, “The Teratogenic Mechanism of 6- Aminonicotinamide on Limb Formation of Chick Embryos: Abnormalities in the Biosynthesis of Glycosaminoglycans and Proteoglycans in Micromelia1,” The Journal of Biochemistry, vol. 91, no. 6. pp. 1959–1970, 1982.
[30] N. Suzuki, S. Ando, N. Yamashita, N. Horie, and K. Saito, “Evaluation of novel high- throughput embryonic stem cell tests with new molecular markers for screening embryotoxic chemicals in vitro,” Toxicol. Sci., vol. 124, no. 2, pp. 460–471, Dec. 2011.
[31] S. M. Gilboa, M. J. Strickland, A. F. Olshan, M. M. Werler, A. Correa, and National Birth Defects Prevention Study, “Use of antihistamine medications during early pregnancy and isolated major malformations,” Birth Defects Res. A Clin. Mol. Teratol., vol. 85, no. 2, pp. 137–150, Feb. 2009.
5.7. 参考文献
[1] “ICH 医薬品規制調和国際会議,” 独立行政法人 医薬品医療機器総合機構. [Online]. Available: https://www.pmda.go.jp/int-activities/int-harmony/ich/0014.html. [Accessed: 2021 年 12 月 1 日].
[2] P. R. West, A. M. Weir, A. M. Smith, E. L. R. Donley, and G. G. Cezar, “Predicting human developmental toxicity of pharmaceuticals using human embryonic stem cells and metabolomics,” Toxicol. Appl. Pharmacol., vol. 247, no. 1, pp. 18–27, Aug. 2010.
[3] J. A. Palmer et al., “Establishment and assessment of a new human embryonic stem cell-based biomarker assay for developmental toxicity screening,” Birth Defects Res. B Dev. Reprod. Toxicol., vol. 98, no. 4, pp. 343–363, 2013.
[4] D. R. Liston and M. Davis, “Clinically Relevant Concentrations of Anticancer Drugs: A Guide for Nonclinical Studies,” Clin. Cancer Res., vol. 23, no. 14, pp. 3489–3498, Jul. 2017.
[5] S. Kameoka, J. Babiarz, K. Kolaja, and E. Chiao, “A high-throughput screen for teratogens using human pluripotent stem cells,” Toxicol. Sci., vol. 137, no. 1, pp. 76– 90, Jan. 2014.
[6] R. Siller, S. Greenhough, E. Naumovska, and G. J. Sullivan, “Small-molecule-driven hepatocyte differentiation of human pluripotent stem cells,” Stem Cell Reports, vol. 4, no. 5, pp. 939–952, May 2015.
[7] N. Aikawa, A. Kunisato, K. Nagao, H. Kusaka, K. Takaba, and K. Ohgami, “Detection of thalidomide embryotoxicity by in vitro embryotoxicity testing based on human iPS cells,” J. Pharmacol. Sci., vol. 124, no. 2, pp. 201–207, Jan. 2014.
[8] N. Aikawa, “A novel screening test to predict the developmental toxicity of drugs using human induced pluripotent stem cells,” J. Toxicol. Sci., vol. 45, no. 4, pp. 187– 199, 2020.
[9] J. Xing, Y.-C. Toh, S. Xu, and H. Yu, “A method for human teratogen detection by geometrically confined cell differentiation and migration,” Sci. Rep., vol. 5, no. 1, p. 10038, May 2015.
[10] Committee for Human Medicinal Products, “ICH S5 (R3) guideline on reproductive toxicology: Detection of toxicity to reproduction for human pharmaceuticals - step 5.” Feb-2020.
[11] D. M. Ornitz and P. J. Marie, “Fibroblast growth factor signaling in skeletal development and disease,” Genes Dev., vol. 29, no. 14, pp. 1463–1486, Jul. 2015.
[12] M. M. El Gendy, A. M. Kandil, M. A. Helal, and F. M. Zahou, “The teratogenic effects of imatinib mesylate on rat fetuses,” Toxicol Rep, vol. 2, pp. 654–663, May 2015.
[13] European Medicines Agency (EMA), “SUMMARY OF PRODUCT CHARACTERISTICS, Pomalidomide Celgene, INN-pomalidomide.” 2013.
[14] C. Mahony, L. Erskine, J. Niven, N. H. Greig, W. D. Figg, and N. Vargesson, “Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro,” Proc. Natl. Acad. Sci. U. S. A., vol. 110, no. 31, pp. 12703– 12708, Jul. 2013.
[15] Committee for Human Medicinal Products, “ICH S5 (R3) guideline on reproductive toxicology: Detection of toxicity to reproduction for human pharmaceuticals - Step 2b.” 2017.
[16] K. Kobayashi et al., “Editor’s Highlight: Development of Novel Neural Embryonic Stem CellTests for High-Throughput Screening of Embryotoxic Chemicals,” Toxicol. Sci., vol. 159, no. 1, pp. 238–250, Sep. 2017.
[17] H. Nagahori, N. Suzuki, F. Le Coz, T. Omori, and K. Saito, “Prediction of in vivo developmental toxicity by combination of Hand1-Luc embryonic stem cell test and metabolic stability test with clarification of metabolically inapplicable candidates,” Toxicol. Lett., vol. 259, pp. 44–51, Sep. 2016.
[18] E. Genschow et al., “Validation of the Embryonic Stem Cell Test in the International ECVAM Validation Study on Three In Vitro Embryotoxicity Tests,” Alternatives to Laboratory Animals, vol. 32, no. 3. pp. 209–244, 2004.
[19] A. Inoue et al., “Comparative study of the zebrafish embryonic toxicity test and mouse embryonic stem cell test to screen developmental toxicity of human pharmaceutical drugs,” Fundamental Toxicological Sciences, vol. 3, no. 2. pp. 79–87, 2016.
[20] F. Uibel and M. Schwarz, “Prediction of embryotoxic potential using the ReProGlo stem cell-based Wnt reporter assay,” Reprod. Toxicol., vol. 55, pp. 30–49, Aug. 2015.
[21] M. E. Matyskiela et al., “SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate,” Nat. Chem. Biol., vol. 14, no. 10, pp. 981–987, Sep. 2018.
[22] S. Yamanaka et al., “Thalidomide and its metabolite 5-hydroxythalidomide induce teratogenicity via the cereblon neosubstrate PLZF,” EMBO J., vol. 40, no. 4, p. e105375, Feb. 2021.
[23] E. S. Fischer et al., “Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide,” Nature, vol. 512, no. 7512, pp. 49–53, Jul. 2014.
[24] R. Eichner et al., “Immunomodulatory drugs disrupt the cereblon–CD147–MCT1 axis to exert antitumor activity and teratogenicity,” Nat. Med., vol. 22, no. 7, pp. 735–743, Jun. 2016.
[25] T. Asatsuma-Okumura, T. Ito, and H. Handa, “Molecular Mechanisms of the Teratogenic Effects of Thalidomide,” Pharmaceuticals , vol. 13, no. 5, May 2020.
[26] Y. Gemechu et al., “Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs,” Proc. Natl. Acad. Sci. U. S. A., vol. 115, no. 46, pp. 11802–11807, Nov. 2018.
[27] B. F. Hales, “Comparison of the Mutagenicity and Teratogenicity of Cyclophosphamide and Its Active Metabolites, 4-Hydroxycyclophosphamide, Phosphoramide Mustard, and Acrolein,” Cancer Res., vol. 42, no. 8, pp. 3016–3021, Aug. 1982.
[28] “Corning® Tissue Fractions Reagents for Drug Metabolism,” Corning. [Online]. Available: https://www.corning.com/media/worldwide/cls/documents/CLS-DL-GT- 020REV2.pdf. [Accessed: 2021 年 10 月 15 日].
[29] B. A. Pandian, R. Sathishraj, M. Djanaguiraman, P. V. V. Prasad, and M. Jugulam, “Role of Cytochrome P450 Enzymes in Plant Stress Response,” Antioxidants (Basel), vol. 9, no. 5, May 2020.
[30] T. L. Chen et al., “Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation,” Cancer Res., vol. 55, no. 4, pp. 810–816, Feb. 1995.
[31] D. A. Ramirez, K. P. Collins, A. E. Aradi, K. A. Conger, and D. L. Gustafson, “Kinetics of Cyclophosphamide Metabolism in Humans, Dogs, Cats, and Mice and Relationship to Cytotoxic Activity and Pharmacokinetics,” Drug Metab. Dispos., vol. 47, no. 3, pp. 257–268, Mar. 2019.c
論文の公開元へ
